GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AddLife AB (OTCPK:ADDLF) » Definitions » Debt-to-EBITDA

AddLife AB (AddLife AB) Debt-to-EBITDA : 7.44 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is AddLife AB Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

AddLife AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $244.4 Mil. AddLife AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $287.5 Mil. AddLife AB's annualized EBITDA for the quarter that ended in Mar. 2024 was $71.5 Mil. AddLife AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 7.44.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for AddLife AB's Debt-to-EBITDA or its related term are showing as below:

ADDLF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.22   Med: 2.46   Max: 10.2
Current: 10.2

During the past 11 years, the highest Debt-to-EBITDA Ratio of AddLife AB was 10.20. The lowest was 0.22. And the median was 2.46.

ADDLF's Debt-to-EBITDA is ranked worse than
94.27% of 436 companies
in the Medical Devices & Instruments industry
Industry Median: 1.26 vs ADDLF: 10.20

AddLife AB Debt-to-EBITDA Historical Data

The historical data trend for AddLife AB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AddLife AB Debt-to-EBITDA Chart

AddLife AB Annual Data
Trend Mar14 Mar15 Mar16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.09 0.85 2.81 3.89 3.45

AddLife AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.37 10.85 10.71 14.86 7.44

Competitive Comparison of AddLife AB's Debt-to-EBITDA

For the Medical Instruments & Supplies subindustry, AddLife AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AddLife AB's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AddLife AB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where AddLife AB's Debt-to-EBITDA falls into.



AddLife AB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

AddLife AB's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(234.265 + 281.352) / 149.548
=3.45

AddLife AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(244.35 + 287.476) / 71.46
=7.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


AddLife AB  (OTCPK:ADDLF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


AddLife AB Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of AddLife AB's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


AddLife AB (AddLife AB) Business Description

Traded in Other Exchanges
Address
Brunkebergstorg 5, Box 3145, Stockholm, SWE, 103 62
AddLife AB is engaged in the business of providing products, services, and advisory services. The company operates in Labtech and Medtech segments. The Labtech segment, which accounts for the majority of the company revenue, provides analytical instruments, equipment, microscopes, consumables, and reagents, as well as software support and technical service. The Medtech segment includes products related to surgery, thoracic medicine, neurology, wound care, anesthesia, intensive care, ear, nose and throat, ostomies, and home healthcare. AddLife mainly caters to hospitals & laboratories within healthcare, research, colleges, and universities, as well as the food and pharmaceutical industries. Its geographical segments are Sweden, Denmark, Finland, Norway, and Other countries.

AddLife AB (AddLife AB) Headlines

From GuruFocus

Full Year 2023 AddLife AB Earnings Call Transcript

By GuruFocus Research 02-05-2024